MBT-826 has potential to inhibit cyclin-dependent kinases (CDKs) and is in drug discovery stage.

MBT-826 is a novel synthesized derivative of the natural product Indigo. Those compounds are strong inhibitors of CDKs, glycogen synthase kinase-3β, c-Src kinase and STAT3 signaling, and an inhibitor of Survivin leading to apoptosis in cancer cells.